Millennium Submits Supplemental New Drug Application with FDA for Long-Term Overall Survival Results of VELCADE in Previously Untreated Multiple Myeloma (Business Wire)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced the submission of a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA) for VELCADE� (bortezomib) for injection to add overall survival (OS) data after a five-year follow up to the product...

Source : Business Wire

Explore : Business, FDA, Health, Health Industries

Source: http://wik.io/info/US/278119757

rss systems rss tehcnology rss wikio technology rss wikio technology computers rss wikio technology operating